These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 23466233)
21. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665 [TBL] [Abstract][Full Text] [Related]
22. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. Belema M; Meanwell NA J Med Chem; 2014 Jun; 57(12):5057-71. PubMed ID: 24749835 [TBL] [Abstract][Full Text] [Related]
23. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Pelosi LA; Voss S; Liu M; Gao M; Lemm JA Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513 [TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. Nakamura H; Akagi Y; Terui T; Fujioka S; Komoda Y; Kinoshita W; Maeda K; Ukaji Y; Inaba T Bioorg Med Chem Lett; 2020 Mar; 30(5):126932. PubMed ID: 31952964 [TBL] [Abstract][Full Text] [Related]
25. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity. Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013 [TBL] [Abstract][Full Text] [Related]
26. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Peng X; Wang C; Ying L; Cao H; Lawitz E; Poordad F; Rondon J; Box TD; Zeuzem S; Buggisch P; Lin K; Qiu YL; Jiang L; Colvin R; Or YS Antimicrob Agents Chemother; 2016 Oct; 60(10):6207-15. PubMed ID: 27503640 [TBL] [Abstract][Full Text] [Related]
27. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983 [TBL] [Abstract][Full Text] [Related]
28. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. Nettles JH; Stanton RA; Broyde J; Amblard F; Zhang H; Zhou L; Shi J; McBrayer TR; Whitaker T; Coats SJ; Kohler JJ; Schinazi RF J Med Chem; 2014 Dec; 57(23):10031-43. PubMed ID: 25365735 [TBL] [Abstract][Full Text] [Related]
29. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816 [TBL] [Abstract][Full Text] [Related]
30. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428 [TBL] [Abstract][Full Text] [Related]
31. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279 [TBL] [Abstract][Full Text] [Related]
32. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development. Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003 [TBL] [Abstract][Full Text] [Related]
33. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163 [TBL] [Abstract][Full Text] [Related]
34. Discovery of potent macrocyclic HCV NS5A inhibitors. Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743 [TBL] [Abstract][Full Text] [Related]
35. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides. Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252 [TBL] [Abstract][Full Text] [Related]
36. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666 [TBL] [Abstract][Full Text] [Related]
37. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Fridell RA; Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Qiu D; Roberts S; Huang X; Kienzle B; Bifano M; Nettles RE; Gao M Hepatology; 2011 Dec; 54(6):1924-35. PubMed ID: 21809362 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798 [TBL] [Abstract][Full Text] [Related]
39. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Sun JH; O'Boyle Ii DR; Zhang Y; Wang C; Nower P; Valera L; Roberts S; Nettles RE; Fridell RA; Gao M Hepatology; 2012 Jun; 55(6):1692-9. PubMed ID: 22234905 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. Shi J; Zhou L; Amblard F; Bobeck DR; Zhang H; Liu P; Bondada L; McBrayer TR; Tharnish PM; Whitaker T; Coats SJ; Schinazi RF Bioorg Med Chem Lett; 2012 May; 22(10):3488-91. PubMed ID: 22507961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]